Ser77Tyr transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features

Author:

Dori Amir12ORCID,Arad Michael23,Wasserstrum Yishay23,Pollak Arthur4,Nikitin Vera12,Ben‐David Merav12,Shamash Jana5,Nahum Ayelet Hashachar5,Shavit‐Stein Efrat12,Domachevsky Liran26,Kuperstein Rafael23,Dominissini Dan278,Shelestovich Natalia29,Sadeh Menachem210,Pras Elon25,Greenbaum Lior2511ORCID

Affiliation:

1. Department of Neurology Sheba Medical Center Tel Hashomer Israel

2. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. The Leviev Heart Center, Sheba Medical Center Tel Hashomer Israel

4. Department of Cardiology, Hadassah Medical Center Hebrew University of Jerusalem Jerusalem Israel

5. The Danek Gertner Institute of Human Genetics, Sheba Medical Center Tel Hashomer Israel

6. Department of Nuclear Medicine Sheba Medical Center Tel Hashomer Israel

7. The genomics Unit Sheba Cancer Research Center, Sheba Medical Center Tel Hashomer Israel

8. Wohl Institute of Translational Medicine, Sheba Medical Center Tel Hashomer Israel

9. Department of Pathology Sheba Medical Center Tel Hashomer Ramat Gan Israel

10. Department of Neurology Wolfson Medical Center Holon Israel

11. The Joseph Sagol Neuroscience Center, Sheba Medical Center Tel Hashomer Israel

Abstract

AbstractObjectiveAmyloidosis due to the transthyretin Ser77Tyr mutation (ATTRS77Y) is a rare autosomal‐dominant disorder, characterized by carpal‐tunnel syndrome, poly‐ and autonomic‐neuropathy, and cardiomyopathy. However, related symptoms and signs are often nonspecific and confirmatory tests are required. We describe the age and frequency of early symptoms and diagnostic features among individuals of Jewish Yemenite descent in Israel.MethodsRecords of mutation carriers were retrospectively reviewed. ATTRS77Y diagnosis was defined by the presence of amyloid in tissue and/or amyloid‐related cardiomyopathy.ResultsWe identified the Ser77Tyr mutation at the heterozygous state in 19 amyloidosis patients (mean age at diagnosis: 62 ± 5.7 years, range 49–70) and 30 amyloid‐negative carriers. The probability for disease diagnosis increased from 4.4% at age 49 to 100% at 70 and occurred earlier in males. Initial symptoms preceded diagnosis by 5 ± 3.8 years (range 0–12) and were commonly sensory changes in the extremities. Erectile dysfunction predated these in 8/13 (62%) males. In two patients cardiac preceded neurological symptoms. Two patients declined symptoms. Electrophysiological studies near the time of diagnosis indicated a median neuropathy at the wrist in 18/19 (95%) and polyneuropathy in 13/19 (68%). Skin biopsy revealed epidermal denervation in 15/16 (94%) patients. Cardiomyopathy was identified in 16/19 (84%). Sensory complaints or epidermal denervations were present in 17/30 (57%) of amyloid‐negative carriers and co‐occurred in 10/30 (33%).InterpretationATTRS77Y symptoms commonly occur after age 50, but may begin earlier. Median neuropathy, skin denervation and cardiomyopathy are frequently identified. Symptoms may be absent in patients and common in amyloid‐negative carriers.

Funder

Pfizer

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3